Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is poised for growth with strong financials and a positive outlook. With a 10% organic revenue increase and plans for international expansion, the company's profitability has improved and they have seen success in M&A with their recent acquisition of Artegraft. Despite risks in compliance and manufacturing, LeMaitre has a record of successful financial performance and a continued focus on growth and investment opportunities.

Bears say

LeMaitre Vascular is expected to see strong performance and growth in international markets due to its recent investments and expansion in those regions, while also benefiting from a favorable pricing environment and increased sales representatives. However, the company's declining sales representatives and lower-than-expected unit volume growth in the first quarter raise concerns about its ability to sustain growth in the long term and highlight potential difficulties in achieving its ambitious sales representative target for 2026. This, along with pressure on pricing moving forward, suggests a cautious outlook for the company's overall revenue and earnings growth.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.